tiprankstipranks
Trending News
More News >
Vital KSK Holdings, Inc. (JP:3151)
:3151
Japanese Market
Advertisement

Vital KSK Holdings, Inc. (3151) AI Stock Analysis

Compare
0 Followers

Top Page

JP

Vital KSK Holdings, Inc.

(3151)

Rating:70Outperform
Price Target:
¥1,340.00
▲(8.50%Upside)
Vital KSK Holdings, Inc. receives a score of 70.2, primarily driven by its solid financial foundation and attractive valuation. However, the company's operational and cash flow inefficiencies, along with neutral technical indicators, present challenges. Investors may find value due to the strong equity base and dividend yield, but should remain cautious of potential liquidity issues.

Vital KSK Holdings, Inc. (3151) vs. iShares MSCI Japan ETF (EWJ)

Vital KSK Holdings, Inc. Business Overview & Revenue Model

Company DescriptionVital KSK Holdings, Inc. engages in the wholesale of pharmaceutical products in Japan. The company is involved in the wholesale of veterinary drugs; agricultural chemicals, agricultural materials, etc.; and medical and nursing care equipment. It also engages in the pharmacy and nursing care businesses; transportation business; insurance agent and real estate management businesses; parking business; mail-order business of health-related products; and pharmacy dispensing business. In addition, the company offers medical management consulting services; and manufactures OTC drugs. The company was founded in 2009 and is headquartered in Tokyo, Japan.
How the Company Makes MoneyVital KSK Holdings, Inc. generates revenue through multiple streams, primarily from the sale of pharmaceuticals, nutritional supplements, and health foods. The company also earns income from its distribution of medical equipment and supplies, serving hospitals, clinics, and other healthcare facilities. Key partnerships with healthcare providers and organizations enhance its market reach and contribute significantly to its earnings. The company's diverse product offerings and strong distribution network are critical factors in its financial performance.

Vital KSK Holdings, Inc. Financial Statement Overview

Summary
Vital KSK Holdings, Inc. shows steady revenue growth and a strong equity position, indicating stability and potential for future growth. However, operational and cash flow inefficiencies present challenges that need addressing to enhance profitability and liquidity.
Income Statement
76
Positive
Vital KSK Holdings, Inc. displays a steady revenue growth rate with a 2.18% increase from the previous year. The gross profit margin stands at 8.20%, which is relatively stable over the years. The net profit margin improved to 1.22%, indicating better profitability. However, the EBIT margin is 0.95%, showing limited operating efficiency. Overall, the company is on a positive growth trajectory but needs to enhance operational efficiency.
Balance Sheet
72
Positive
The company maintains a strong equity base with a debt-to-equity ratio of 0.08, indicating low leverage. The return on equity (ROE) is 6.90%, reflecting moderate returns to shareholders. With an equity ratio of 35.36%, Vital KSK Holdings has a stable financial structure. Despite the solid foundation, greater returns and asset utilization could augment shareholder value.
Cash Flow
65
Positive
Vital KSK Holdings faces challenges with its cash flow, marked by negative operating cash flow. The free cash flow is also negative, affecting liquidity. The operating cash flow to net income ratio is -1.10, indicating inefficiencies in converting income to cash. Improvement in cash management and operational efficiencies are vital for better financial health.
BreakdownMar 2025Mar 2024Mar 2023Mar 2022Mar 2021
Income Statement
Total Revenue600.37B587.48B579.77B577.25B537.06B
Gross Profit49.22B48.30B44.96B43.98B38.22B
EBITDA14.56B12.16B5.82B6.07B939.00M
Net Income7.31B5.84B4.83B4.77B1.17B
Balance Sheet
Total Assets299.43B317.26B297.32B313.03B311.40B
Cash, Cash Equivalents and Short-Term Investments23.10B34.71B19.03B26.97B29.78B
Total Debt8.59B9.11B10.25B11.85B16.80B
Total Liabilities192.12B211.32B197.15B212.99B207.49B
Stockholders Equity105.91B104.66B98.98B98.96B102.94B
Cash Flow
Free Cash Flow-10.59B18.47B-9.60B3.35B-5.23B
Operating Cash Flow-8.02B23.57B-3.00B7.49B-1.39B
Investing Cash Flow3.52B-1.82B-1.04B-2.01B549.00M
Financing Cash Flow-6.54B-5.77B-4.08B-8.49B-2.52B

Vital KSK Holdings, Inc. Technical Analysis

Technical Analysis Sentiment
Positive
Last Price1235.00
Price Trends
50DMA
1231.52
Negative
100DMA
1231.68
Negative
200DMA
1210.77
Positive
Market Momentum
MACD
1.13
Negative
RSI
55.00
Neutral
STOCH
83.06
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:3151, the sentiment is Positive. The current price of 1235 is above the 20-day moving average (MA) of 1203.85, above the 50-day MA of 1231.52, and above the 200-day MA of 1210.77, indicating a neutral trend. The MACD of 1.13 indicates Negative momentum. The RSI at 55.00 is Neutral, neither overbought nor oversold. The STOCH value of 83.06 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:3151.

Vital KSK Holdings, Inc. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (65)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
76
Outperform
¥6.75B10.60
2.31%3.06%-6.60%
70
Outperform
¥55.57B8.29
3.89%2.19%30.09%
65
Neutral
€6.38B19.89-1.30%2.25%-0.16%-45.39%
$362.31M57.881.87%0.02%
70
Outperform
¥38.12B18.85
3.91%11.04%20.33%
69
Neutral
¥12.64B9.33
3.85%3.95%-11.14%
53
Neutral
¥75.98B
3.33%-22.86%-188.19%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
JP:3151
Vital KSK Holdings, Inc.
1,229.00
-73.52
-5.64%
HGYMF
Hogy Medical Co
25.49
-3.06
-10.72%
JP:2689
OLBA HEALTHCARE HOLDINGS, Inc.
2,055.00
71.44
3.60%
JP:3183
WIN-Partners Co., Ltd.
1,308.00
112.92
9.45%
JP:4552
JCR Pharmaceuticals Co., Ltd.
686.00
70.63
11.48%
JP:9265
YAMASHITA HEALTH CARE HOLDINGS, INC.
2,649.00
100.81
3.96%

Vital KSK Holdings, Inc. Corporate Events

Vital KSK Holdings Announces Treasury Stock Disposal for Performance-Linked Compensation
Jul 1, 2025

Vital KSK Holdings, Inc. has announced the disposal of its treasury stock as part of a performance-linked restricted stock compensation plan. This initiative aims to align the interests of its directors and executive officers with the company’s performance by issuing 102,304 shares of common stock. The move is designed to motivate these individuals to enhance corporate value and share in the benefits and risks associated with stock price changes. The plan, approved in 2023, outlines specific performance targets and conditions for the allocation of stock, impacting directors, executive officers, and employees across the company and its subsidiaries.

Vital KSK Holdings Announces Leadership Restructuring
Jul 1, 2025

Vital KSK Holdings, Inc. has announced a series of changes in its board of directors and executive officers, effective from late June to July 2025. These changes aim to enhance the company’s strategic planning and operational efficiency, potentially impacting its market position and stakeholder relations positively.

Vital KSK Holdings Announces Treasury Stock Disposal for Compensation
Jun 26, 2025

Vital KSK Holdings, Inc. has announced a decision by its Board of Directors to dispose of treasury stock as part of a performance-linked restricted stock compensation plan. This move is likely aimed at aligning the interests of its executives with company performance, potentially impacting shareholder value and executive motivation.

Vital KSK Holdings Revises Director Compensation Plan to Boost Corporate Value
May 22, 2025

Vital KSK Holdings, Inc. has announced a partial revision to its performance-linked restricted stock compensation plan for its directors, aiming to better align director incentives with shareholder interests and corporate performance. The changes include a new method for calculating performance payment ratios based on return on equity, which is intended to more accurately reflect the company’s business plans and performance levels, thereby enhancing the motivation of directors to contribute to long-term corporate value growth.

Vital KSK Holdings Announces Strategic Organizational and Personnel Changes
May 22, 2025

Vital KSK Holdings, Inc. announced significant organizational and personnel changes, including the merging of departments and the appointment of new directors and executive officers. These changes aim to streamline operations and enhance focus on sustainability and new business development, potentially impacting the company’s strategic direction and stakeholder engagement.

Vital KSK Holdings to Amend Articles for Business Expansion
May 21, 2025

Vital KSK Holdings, Inc. has announced proposed amendments to its Articles of Incorporation, aiming to expand and diversify its business operations beyond pharmaceutical wholesale. This strategic move is intended to bolster the company’s earning power by including health-related services and other emerging business opportunities, reflecting a significant shift in its operational focus.

Vital KSK Holdings Reports Growth in Fiscal Year 2025
May 14, 2025

Vital KSK Holdings, Inc. reported a 2.2% increase in net sales for the fiscal year ending March 31, 2025, with a notable 25.1% rise in profit attributable to owners of the parent. The company also announced an increase in cash dividends per share, reflecting a positive outlook despite a decrease in comprehensive income. The financial results indicate a stable growth trajectory, with a forecasted increase in net sales and dividends for the next fiscal year, suggesting confidence in future performance.

Vital KSK Holdings Announces Treasury Stock Disposition for Compensation Plan
May 14, 2025

Vital KSK Holdings, Inc. announced its plan to dispose of treasury stock as part of a performance-linked restricted stock compensation plan approved in 2023. This move, involving an estimated 128,400,000 yen, aims to incentivize directors, executive officers, and eligible employees, potentially impacting the company’s financial structure and stakeholder interests.

Vital KSK Holdings Announces Stable Dividend Payout
May 14, 2025

Vital KSK Holdings, Inc. has announced a dividend of 24.00 yen per share for the fiscal year ended March 31, 2025, reflecting its commitment to returning profits to shareholders. The company aims for a dividend on equity ratio of 2% or more and a total return ratio policy of 50% or more, indicating a focus on shareholder value.

Vital KSK Holdings Amends Stock Compensation Plan
May 14, 2025

Vital KSK Holdings, Inc. announced a resolution to amend its Performance-Linked Restricted Stock Compensation Plan, which will be proposed at the upcoming Annual General Meeting of Shareholders. This amendment reflects the company’s ongoing efforts to align executive compensation with performance, potentially impacting shareholder value and corporate governance practices.

Vital KSK Holdings Proposes Amendments to Articles of Incorporation
May 14, 2025

Vital KSK Holdings, Inc. has announced a resolution to propose amendments to its Articles of Incorporation at the upcoming Annual General Meeting of Shareholders. This move could potentially impact the company’s governance structure and align its operations with strategic goals, affecting stakeholders and market positioning.

Vital KSK Holdings Announces Organizational and Leadership Changes
May 14, 2025

Vital KSK Holdings, Inc. has announced a series of organizational changes, including updates to its representative directors, directors, and executive officers. These changes will be finalized at the upcoming Annual General Meeting of Shareholders and are expected to impact the company’s governance structure and operational leadership.

Vital KSK Holdings Unveils Medium-Term Management Plan 2027
May 1, 2025

Vital KSK Holdings, Inc. has announced its Medium-Term Management Plan 2027, titled ‘Move on to the Next Stage,’ which outlines the company’s strategic initiatives for the next three years starting from FY2025. This plan is expected to guide the company through its next phase of growth, potentially impacting its operational strategies and market positioning.

Vital KSK Holdings Secures Exclusive License for Iron Deficiency Treatment in Japan
Apr 22, 2025

Vital KSK Holdings, Inc. announced that its subsidiary, VITAL-NET, Inc., has entered into an exclusive license agreement with Shield Therapeutics plc for the development and commercialization of ACCRUFeR®, an iron deficiency treatment, in Japan. This strategic move aims to expand Vital KSK’s pharmaceutical offerings in Japan, with plans to build a comprehensive distribution and sales network. The agreement involves upfront and milestone payments, as well as royalties, and is expected to enhance the company’s market position and product value chain.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 11, 2025